1-4 of 4
H. Opitz
Close
Sort by
Journal Articles

Comparison of LIC Obtained from Biopsy, BLS and R 2 -MRI in Iron Overloaded Patients with β-Thalassemia, Treated with Deferasirox (Exjade®, ICL670).

A. Piga, R. Fischer, P. Harmatz, T. G. St. Pierre, F. Longo, E. Fung, R. Engelhardt, S. Perrotta, R. Galanello, M. Capra, E. Vichinsky, G. Janka-Schaub, G. Masera, P. Cianciulli, T. Coates, G. Janssen, M. Jeng, M. E. Lai, G. Salles, P. Cole, D. Alberti, G. Rosenkranz, H. Opitz
Journal: Blood
Blood (2005) 106 (11): 2689.
https://doi.org/10.1182/blood.V106.11.2689.2689
Published: 2005
Journal Articles

Iron Chelation Efficiency of Deferasirox (Exjade®, ICL670) in Patients with Transfusional Hemosiderosis.

J. Porter, C. Borgna-Pignatti, M. Baccarani, A. Saviano, S. Abish, R. Malizia, H. Nick, H. Opitz, B. Rabault, I. Gathmann, P. Marks
Journal: Blood
Blood (2005) 106 (11): 2690.
https://doi.org/10.1182/blood.V106.11.2690.2690
Published: 2005
Journal Articles

Patient Satisfaction with Deferasirox (Exjade ® , ICL670) an Oral Form of Chelation Therapy Versus Deferoxamine an Infused Chelation Therapy.

M.D. Cappellini, M. Bejaoui, L. Agaoglu, M.E. Lai, A. Mangiagli, G. Strauss, R. Girot, H. Opitz, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, J. Ford
Journal: Blood
Blood (2005) 106 (11): 2704.
https://doi.org/10.1182/blood.V106.11.2704.2704
Published: 2005
Journal Articles

Effect of Iron Intake on Control of Body Iron in Patients with Thalassemia Major Treated with Deferasirox (Exjade®, ICL670).

A. Cohen, G. Masera, N. Zoumbos, Z. Uysal, D. Boulet, N. Watman, S. Loggetto, H. Opitz, I. Gathmann, D. Alberti
Journal: Blood
Blood (2005) 106 (11): 822.
https://doi.org/10.1182/blood.V106.11.822.822
Published: 2005